Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Amiodarone:SCnc:Pt:Ser/Plas:Qn

Known as: Amiodarone:Substance Concentration:Point in time:Serum/Plasma:Quantitative, amiodarona:concentración de sustancia:punto en el tiempo:suero/plasma:cuantitativo, ?????:????:????:??/??:?? 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Resumen Introduccion y objetivos Recientemente se han producido numerosas novedades en el manejo de la fibrilacion auricular no… Expand
Is this relevant?
2012
2012
Resumen Objetivo Conocer la incidencia de prescripciones potencialmente inapropiadas (PPI) de los pacientes mayores de 65 anos… Expand
Is this relevant?
2009
2009
Amiodaron gehört zu den Klasse-III-Antiarrhythmika und ist ein wirksames Medikament zur Behandlung von atrialen und ventrikulären… Expand
Is this relevant?
2008
2008
ZusammenfassungEINLEITUNG: Ziel dieser Studie war die Erfassung von Inzidenz und Prädiktabilität der Amiodaron-induzierten… Expand
  • table 1
  • figure 1
  • table 2
  • table 3
Is this relevant?
2008
2008
Introduccion y objetivos Conocer en la practica clinica el uso de antiarritmicos tras cardioversion electrica en pacientes sin… Expand
  • figure 1
Is this relevant?
2006
2006
Resumo A amiodarona e um eficaz farmaco anti-arritmico usado para tratar arritmias ventriculares e supra-ventriculares, mas nao… Expand
  • figure 1
  • figure 2
  • figure 4
  • figure 5
Is this relevant?
2005
2005
Amiodaron ist ein haufig verwendetes Medikament zur Behandlung von Herzrhythmusstorungen. Das Nebenwirkungsspektrum ist breit und… Expand
Is this relevant?
2000
2000
Background: Optic neuropathy has been reported to occur during antiarrhythmic therapy with amiodarone. Whether or not there is a… Expand
Is this relevant?
1978
1978
The antianginal drug amiodarone (an amphiphilic cationic compound) causes a keratopathy in humans. In the present investigation… Expand
  • figure 1
  • figure 2
  • figure 4
Is this relevant?